2025-2026 Enduring Program: Empowering Patients with Anti-Obesity Medications

Course Instructions

Registration is required for all live Accredited CME events. Please be sure to register in order to receive the video login for this activity.

Thursday, February 20, 2025, 6:30 PM - Saturday, February 19, 2028, 7:30 PM, Online Enduring

In 2022, approximately 1 in 8 people worldwide were living with obesity. Over the past year, half of individuals reported attempting to lose weight. However, despite these efforts, studies show that 80-95% of people who lose weight regain it within 3-5 years, often due to biological, psychological, and environmental factors. This activity is designed to help primary care providers learn ways to support patients who want to lose weight or are already under the care of a bariatric specialist. Providers will learn about the physiology of obesity, FDA-approved weight loss medications, and how to use them in clinical practice.

1. Explain and evaluate the effectiveness of anti-obesity medications.
2. Analyze the latest guidelines and recommendations for anti-obesity medications.
3. Integrate lifestyle modifications to develop weight loss treatment plans.

AMA PRA Category 1 Credits™ (1.00 hours), ABIM MOC Part 2 (1.00 hours), Non-Physician Attendance (1.00 hours)

Endeavor Health: Edward-Elmhurst Hospitals is accredited by the Illinois State Medical Society to provided accredited continuing medical education. Endeavor Health: Edward-Elmhurst Hospitals designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Mitigation of Relevant Financial Relationships

Endeavor Health: Edward-Elmhurst Hospitals Accredited CME Program adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited CME activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.